These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 24053191)

  • 21. An update on the safety of lanreotide autogel for the treatment of patients with neuroendocrine tumors.
    Sood A; Munir M; Syed O; Mehta V; Kaur R; Kumar A; Sridhar A; Sood A; Gupta R
    Expert Opin Drug Saf; 2024 Aug; 23(8):949-957. PubMed ID: 38847075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of advanced BP-NETS with lanreotide autogel/depot vs placebo: the phase III SPINET study.
    Baudin E; Capdevila J; Hörsch D; Singh S; Caplin ME; Wolin EM; Buikhuisen W; Raderer M; Dansin E; Grohe C; Ferone D; Houchard A; Truong-Thanh XM; Reidy-Lagunes D
    Endocr Relat Cancer; 2024 Sep; 31(9):. PubMed ID: 38913539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Antiproliferative Effect of Somatostatin Analogs -  Data Analyses and Clinical Applications in the Context of the CLARINET Study].
    Bencsiková B
    Klin Onkol; 2016; 29(4):253-8. PubMed ID: 27534781
    [TBL] [Abstract][Full Text] [Related]  

  • 24. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study.
    Jimenez-Fonseca P; Carmona-Bayonas A; Lamarca A; Barriuso J; Castaño A; Benavent M; Alonso V; Riesco MDC; Alonso-Gordoa T; Custodio A; Sanchez Canovas M; Hernando J; López C; La Casta A; Fernandez Montes A; Marazuela M; Crespo G; Diaz JA; Feliciangeli E; Gallego J; Llanos M; Segura A; Vilardell F; Percovich JC; Grande E; Capdevila J; Valle J; Garcia-Carbonero R
    Neuroendocrinology; 2022; 112(1):88-100. PubMed ID: 33508849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
    Palazzo M; Lombard-Bohas C; Cadiot G; Matysiak-Budnik T; Rebours V; Vullierme MP; Couvelard A; Hentic O; Ruszniewski P
    Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):232-8. PubMed ID: 23108416
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical utility of lanreotide Autogel
    Paragliola RM; Prete A; Papi G; Torino F; Corsello A; Pontecorvi A; Corsello SM
    Drug Des Devel Ther; 2016; 10():3459-3470. PubMed ID: 27822010
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).
    Ferone D; Martin W; Williams J; Houchard A; Pommie C; Ribeiro-Oliveira A; Grossman AB
    J Endocrinol Invest; 2024 Feb; 47(2):421-432. PubMed ID: 37550552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antitumour activity of somatostatin analogues in sporadic, progressive, metastatic pulmonary carcinoids.
    Sullivan I; Le Teuff G; Guigay J; Caramella C; Berdelou A; Leboulleux S; Déandréis D; Hadoux J; Ducreux M; Duvillard P; Adam J; Scoazec JY; Baudin E; Planchard D
    Eur J Cancer; 2017 Apr; 75():259-267. PubMed ID: 28242503
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Escalated-dose somatostatin analogues for antiproliferative effect in GEPNETS: a systematic review.
    Chan DL; Ferone D; Albertelli M; Pavlakis N; Segelov E; Singh S
    Endocrine; 2017 Sep; 57(3):366-375. PubMed ID: 28726183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Octreotide acetate long-acting release in patients with metastatic neuroendocrine tumors pretreated with lanreotide.
    Ricci S; Antonuzzo A; Galli L; Ferdeghini M; Bodei L; Orlandini C; Conte PF
    Ann Oncol; 2000 Sep; 11(9):1127-30. PubMed ID: 11061606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours.
    Aparicio T; Ducreux M; Baudin E; Sabourin JC; De Baere T; Mitry E; Schlumberger M; Rougier P
    Eur J Cancer; 2001 May; 37(8):1014-9. PubMed ID: 11334727
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and Safety of Lanreotide Autogel and Temozolomide Combination Therapy in Progressive Thoracic Neuroendocrine Tumors (Carcinoid): Results from the Phase 2 ATLANT Study.
    Ferolla P; Berruti A; Spada F; Brizzi MP; Ibrahim T; Marconcini R; Giuffrida D; Amoroso V; La Salvia A; Vaccaro V; Faggiano A; Colao A; Volante M; Ghizzoni S; Mazzanti P; Houchard A; Fazio N
    Neuroendocrinology; 2023; 113(3):332-342. PubMed ID: 36044870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours: An international double-blind, placebo-controlled randomised phase II trial - Prodige 31 REMINET: An FFCD study.
    Lepage C; Phelip JM; Lievre A; Le-Malicot K; Dahan L; Tougeron D; Toumpanakis C; Di-Fiore F; Lombard-Bohas C; Borbath I; Coriat R; Lecomte T; Guimbaud R; Petorin C; Legoux JL; Michel P; Scoazec JY; Smith D; Walter T
    Eur J Cancer; 2022 Nov; 175():31-40. PubMed ID: 36087395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lanreotide for the treatment of gastroenteropancreatic neuroendocrine tumors.
    Saif MW
    Expert Opin Pharmacother; 2016; 17(3):443-56. PubMed ID: 26635177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient satisfaction and preferences of lanreotide Autogel treatment in acromegaly.
    Witek P; Mucha S; Ruchała M
    Endokrynol Pol; 2016; 67(6):572-579. PubMed ID: 28042650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors.
    Ricci S; Antonuzzo A; Galli L; Orlandini C; Ferdeghini M; Boni G; Roncella M; Mosca F; Conte PF
    Am J Clin Oncol; 2000 Aug; 23(4):412-5. PubMed ID: 10955874
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evaluating lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumours.
    Lepage C; Dahan L; Bouarioua N; Toumpanakis C; Legoux JL; Le Malicot K; Guimbaud R; Smith D; Tougeron D; Lievre A; Cadiot G; Di Fiore F; Bouhier-Leporrier K; Hentic O; Faroux R; Pavel M; Borbath I; Valle JW; Rinke A; Scoazec JY; Ducreux M; Walter T
    Dig Liver Dis; 2017 May; 49(5):568-571. PubMed ID: 28292641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Phase II clinical trial of pasireotide long-acting repeatable in patients with metastatic neuroendocrine tumors.
    Cives M; Kunz PL; Morse B; Coppola D; Schell MJ; Campos T; Nguyen PT; Nandoskar P; Khandelwal V; Strosberg JR
    Endocr Relat Cancer; 2015 Feb; 22(1):1-9. PubMed ID: 25376618
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lessons from a multicentre retrospective study of peptide receptor radionuclide therapy combined with lanreotide for neuroendocrine tumours: a need for standardised practice.
    Prasad V; Srirajaskanthan R; Toumpanakis C; Grana CM; Baldari S; Shah T; Lamarca A; Courbon F; Scheidhauer K; Baudin E; Truong Thanh XM; Houchard A; Dromain C; Bodei L
    Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2358-2371. PubMed ID: 32062681
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term results of treatment of malignant carcinoid syndrome with prolonged release Lanreotide (Somatuline Autogel).
    Khan MS; El-Khouly F; Davies P; Toumpanakis C; Caplin ME
    Aliment Pharmacol Ther; 2011 Jul; 34(2):235-42. PubMed ID: 21585408
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.